HFS
ACAD icon

Hantz Financial Services’s Acadia Pharmaceuticals ACAD Stock Holding History

Hantz Financial Services’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$79K Buy
3,129
+648
+26% +$14.3K ﹤0.01% 1470
2026
Q1 		$55K Buy
2,481
+1,521
+158% +$36.3K ﹤0.01% 1514
2025
Q4 		$26K Buy
960
+342
+55% +$8.17K ﹤0.01% 1674
2025
Q3 		$13K Buy
618
+466
+307% +$11K ﹤0.01% 1725
2025
Q2 		$3K Buy
152
+150
+7,500% +$2.79K ﹤0.01% 1864
2025
Q1 		$0 Buy
+2
New +$36 ﹤0.01% 1652

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Hantz Financial Services's ACAD Position: Q2 2026 in Review

Hantz Financial Services increased its Acadia Pharmaceuticals (ACAD) stake by 26% in Q2 2026, buying an estimated $14.3K and bringing the position to 3,129 shares worth $79K. The position accounts for ﹤0.01% of the portfolio, ranked #1470.

Hantz Financial Services first reported a position in ACAD in Q1 2025 and has held it in 6 quarters since. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Hantz Financial Services held 3,129 shares of Acadia Pharmaceuticals worth $79K as of Q2 2026.
  • Hantz Financial Services bought 648 Acadia Pharmaceuticals shares in Q2 2026, an estimated $14.3K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #1470 holding.
  • Hantz Financial Services first reported a position in Acadia Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.